Pharmaceuticals company Innova Captab announced Q1FY26 results Revenue from Operations recorded robust growth of 19% YoY, reaching Rs 351.5 crore in Q1FY26, driven by introduction of new products (including that from newly commissioned Jammu plant) and market expansion. Consolidated EBITDA stood at Rs 56.6 crore vs Rs 44.3 crore in Q1FY25 signifying solid YoY growth of 28%. EBITDA margins improved to 16.1% vs 15.1% in Q1FY25, mainly supported by expanded gross margin. PAT increased by 5% YoY to Rs 31.0 crore, reflecting resilience in the face of increased depreciation and finance expenses. PAT margin stood at 8.8%. Vinay Lohariwala, Managing Director, Innova Captab, said: “The first quarter has provided us with a strong and confident start to the financial year 2026. We delivered solid growth, reflected in both a healthy expansion of our topline and a notable improvement in operating profitability. We continued to make steady progress on our strategic initiatives, in line with our plans. Our newly commissioned facility in Jammu gained momentum during the quarter, and we expect this traction to accelerate in the coming quarters and beyond. In a pivotal move, we have reorganized our business areas into two focused verticals: CDMO and Branded Generics to synchronize with our strategic vision. Over the years, we’ve built robust partnerships with our CDMO clients across global markets, while simultaneously strengthening our direct presence in India and other key international geographies. We remain committed to executing our strategy with discipline and agility. With a strong foundation in place, we are confident in our ability to drive sustainable growth and longterm value for all stakeholders.” Result PDF